| UFT/leucovorin plus vinorelbine combination for advanced breast cancer. | |
| | |
MedLine Citation:
|
PMID: 11098494 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This phase I study was undertaken to define the maximum tolerated dose, the dose-limiting toxicity, and the recommended dose of UFT plus leucovorin and vinorelbine in combination treatment of patients with metastatic breast cancer previously treated with one chemotherapy regimen. The pharmacokinetics of UFT and vinorelbine were also evaluated. Patients were treated with escalating doses of UFT and vinorelbine, given every 4 weeks. At least three patients were treated at each dose level before escalating to the next level. As of September 1, 1999, 22 patients have been treated. Eighteen patients were evaluable for antitumor response. One patient had a complete response (which was obtained after three cycles); four patients had a partial response. The area under the concentration-time curve (AUC0-6 h) of 5-fluorouracil increase was more than dose-proportional. The AUC0-6 h values of fluorouracil were significantly higher than those noted for the four patients who developed dose-limiting toxicity at day 15. The removal of one administration of vinorelbine at dose levels 3 and 4 has allowed for increased UFT dosage and AUC0-6 h of fluorouracil, with no dose-limiting toxicity reported for these patients. No pharmacokinetic interaction between UFT and vinorelbine was observed. |
| | |
Authors:
|
P Fumoleau; R Déporte; P Kerbrat; J Bonneterre; P Fargeot |
Related Documents
:
|
15028404 - Phase i study of uft plus leucovorin with radiotherapy in patients with inextirpable no... 12967734 - Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly ... 18809314 - An eortc phase i study of bortezomib in combination with oxaliplatin, leucovorin and 5-... 2521184 - Phase ii trials of the serotonin antagonist gr38032f for the control of vomiting caused... 1629514 - Tannin content of tea and coffee. 18662264 - Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin... |
Publication Detail:
|
Type: Clinical Trial; Clinical Trial, Phase I; Journal Article |
Journal Detail:
|
Title: Oncology (Williston Park, N.Y.) Volume: 14 ISSN: 0890-9091 ISO Abbreviation: Oncology (Williston Park, N.Y.) Publication Date: 2000 Oct |
Date Detail:
|
Created Date: 2001-02-12 Completed Date: 2001-03-01 Revised Date: 2006-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 8712059 Medline TA: Oncology (Williston Park) Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 50-5 Citation Subset: IM |
Affiliation:
|
Medical Oncology Department, Centre René Gauducheau, Nantes, France. fumoleau@nantes.fnclcc.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adult Aged Antineoplastic Agents, Phytogenic / adverse effects, pharmacokinetics, therapeutic use* Antineoplastic Combined Chemotherapy Protocols / administration & dosage, adverse effects, pharmacokinetics, therapeutic use* Area Under Curve Breast Neoplasms / drug therapy*, pathology Dose-Response Relationship, Drug Female Humans Injections, Intravenous Leucovorin / administration & dosage Middle Aged Tegafur / administration & dosage, pharmacokinetics Treatment Outcome Uracil / administration & dosage, pharmacokinetics Vinblastine / adverse effects, analogs & derivatives*, pharmacokinetics, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Phytogenic; 17902-23-7/Tegafur; 58-05-9/Leucovorin; 66-22-8/Uracil; 71486-22-1/vinorelbine; 74578-38-4/1-UFT protocol; 865-21-4/Vinblastine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer.
Next Document: A phase I study. Preoperative UFT/leucovorin and radiation therapy in rectal cancer.